PD Dr. Stefan Diem
Medizinische Onkologie und Hämatologie · Dept. I
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Wyss N, Berner F, Walter V, Jochum A, Purde M, Abdou M, Sinnberg T, Hofmeister K, Pop O, Hasan A, Bauer J, Cheng H, Lütge M, Klümper N, Diem S, Kosaloglu-Yalcin Z, Zhang Y, Sellmer L, Macek B, Karbach J, König D, Läubli H, Zender L, Meyer B, Driessen C, Schürch C, Jochum W, Amaral T, Heinzerling L, Cozzio A, Hegazy A, Schneider T, Brutsche M, Sette A, Lenz T, Walz J, Rammensee H, Früh M, Jäger E, Becher B, Tufman A, Núñez N, Jörger M, Flatz L. Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade. Am J Respir Crit Care Med 2024; 210:919-930.
Oct 1, 2024Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Oct 1, 2024Am J Respir Crit Care Med 2024; 210:919-930
Wyss Nina, Berner Fiamma, Walter Vincent, Jochum Ann-Kristin, Purde Mette T, Abdou Marie-Therese, Sinnberg Tobias, Hofmeister Kathrin, Pop Oltin, Hasan Ali, Bauer Jens, Cheng Hung-Wei, Lütge Mechthild, Klümper Niklas, Diem Stefan, Kosaloglu-Yalcin Zeynep, Zhang Yizheng, Sellmer Laura, Macek Boris, Karbach Julia, König David, Läubli Heinz, Zender Lars, Meyer Britta S, Driessen Christoph, Schürch Christian M, Jochum Wolfram, Amaral Teresa, Heinzerling Lucie M, Cozzio Antonio, Hegazy AhN, Schneider Tino, Brutsche Martin, Sette Alessandro, Lenz Tobias L, Walz Juliane Sarah, Rammensee Hans-Georg, Früh Martin, Jäger Elke, Becher Burkhard, Tufman Amanda, Núñez Nicolás Gonzalo, Jörger Markus, Flatz Lukas
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol 2022; 7:eabn9644.
Sep 2, 2022Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Sep 2, 2022Sci Immunol 2022; 7:eabn9644
Berner Fiamma, Bomze David, Lichtensteiger Christa, Walter Vincent, Niederer Rebekka, Hasan Ali Omar, Wyss Nina, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Abdou Marie-Therese, Diem Stefan, Knöpfli Stella, Sinnberg Tobias, Hofmeister Kathrin, Cheng Hung-Wei, Toma Marieta, Klümper Niklas, Purde Mette-Triin, Pop Oltin Tiberiu, Jochum Ann-Kristin, Pascolo Steve, Jörger Markus, Früh Martin, Jochum Wolfram, Rammensee Hans-Georg, Läubli Heinz, Hölzel Michael, Neefjes Jacques, Walz Juliane, Flatz Lukas
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind F, Ellinger J, Brossart P, Diem S, Schmid S, Jörger M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. J Immunother Cancer 2022; 10
Mar 1, 2022C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
Mar 1, 2022J Immunother Cancer 2022; 10
Klümper Niklas, Saal Jonas, Berner Fiamma, Lichtensteiger Christa, Wyss Nina, Heine Annkristin, Bauernfeind Franz Georg, Ellinger Jörg, Brossart Peter, Diem Stefan, Schmid Sabine, Jörger Markus, Frueh Martin, Ritter Manuel, Hölzel Michael, Flatz Lukas, Bald Tobias
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
Dec 7, 2021Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Dec 7, 2021J Cancer Res Clin Oncol 2021; 148:647-656
Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Jörger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Lukas
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
Herbrand A, Hemkens L, Novak U, Moffa G, Jörger M, Hoogkamer A, Diem S, Goldkuhle M, Ewald H, Briel M, Schmitt A, Kasenda B. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw Open 2021; 4:e210380.
Mar 1, 2021Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
Mar 1, 2021JAMA Netw Open 2021; 4:e210380
Herbrand Amanda Katherina, Hemkens Lars G, Novak Urban, Moffa Giusi, Jörger Markus, Hoogkamer Anouk, Diem Stefan, Goldkuhle Marius, Ewald Hannah, Briel Matthias, Schmitt Andreas M, Kasenda Benjamin
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. J Immunother Cancer 2021; 9
Jan 1, 2021Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study
Jan 1, 2021J Immunother Cancer 2021; 9
Wagner Nikolaus, Schraag Amadeus, Klumpp Bernhard, Hoetzenecker Wolfram, Berking Carola, Richtig Erika, Ziemer Mirjana, Mangana Johanna, Terheyden Patrick, Loquai Carmen, Nguyen Van Anh, Gebhardt Christoffer, Meier Friedegund, Diem Stefan, Cozzio Antonio, Flatz Lukas, Röcken Martin, Garbe Claus, Gassenmaier Maximilian, Weide Benjamin, Leiter Ulrike, Lenders Max M, Kühl Kathrin, Reinhardt Lydia, André Fiona, Dudda Milena, Ring Natalie, Ebel Chiara, Stäger Ramon, Zellweger Caroline, Lang Roland, Paar Michael, Gussek Philipp, Richtig Georg, Stürmer Suzan H, Kimeswenger Susanne, Oellinger Angela, Forschner Andrea, Eigentler Thomas K
First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor
Bickel A, Diem S, Flatz L, Stinn B, Siano M. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor. J Cancer Res Ther 2021; 17:276-278.
Jan 1, 2021First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor
Jan 1, 2021J Cancer Res Ther 2021; 17:276-278
Bickel Angelika, Diem Stefan, Flatz Lukas, Stinn Björn, Siano Marco
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunol Immunother 2020; 70:563-568.
Aug 17, 2020Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients
Aug 17, 2020Cancer Immunol Immunother 2020; 70:563-568
Hasan Ali Omar, Hundsberger Thomas, Diem Stefan, Müller Stefanie, Pop Oltin, Markert Eva, Müller Joachim, Moulin Alexandre, Ring Sandra, Ackermann Christoph Jakob, Berner Fiamma, Flatz Lukas
Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
Favara D, Larkin J, Powell N, Turajlic S, Chauhan D, Diem S, Daniels E, Clark J, Au L, Spain L, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open 2020; 5
Jan 1, 2020Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
Jan 1, 2020ESMO Open 2020; 5
Favara David M, Larkin James M, Powell Nick, Turajlic Samra, Chauhan Dharmisha, Diem Stefan, Daniels Ella, Clark James, Au Lewis, Spain Lavinia, Yousaf Nadia
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Herbrand A, Hemkens L, Sricharoenchai S, Novak U, Mc Cord K, Jörger M, Hoogkamer A, Ewald H, Diem S, Briel M, Schmitt A, Kasenda B. Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. ESMO Open 2019; 4:e000596.
Dec 1, 2019Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project
Dec 1, 2019ESMO Open 2019; 4:e000596
Herbrand Amanda Katherina, Hemkens Lars G, Sricharoenchai Sirintip, Novak Urban, Mc Cord Kimberly Alba, Jörger Markus, Hoogkamer Anouk, Ewald Hannah, Diem Stefan, Briel Matthias, Schmitt Andreas Michael, Kasenda Benjamin
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 2019; 82:854-861.
Aug 23, 2019BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
Aug 23, 2019J Am Acad Dermatol 2019; 82:854-861
Hasan Ali Omar, Sadik Christian D, Zillikens Detlef, Schmidt Enno, Jochum Wolfram, Mani Bernhard, Cozzio Antonio, Braun Anne, Emtenani Shirin, Hammers Christoph, Abdou Marie-Therese, Diem Stefan, Fässler Mirjam, Berner Fiamma, Ring Sandra S, Bomze David, Flatz Lukas
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. JAMA Oncol 2019; 5:1043-1047.
Jul 1, 2019Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
Jul 1, 2019JAMA Oncol 2019; 5:1043-1047
Berner Fiamma, Hartmann Fabienne, Cheng Hung-Wei, Hönger Gideon, Recher Mike, Goldman Jonathan, Cozzio Antonio, Früh Martin, Neefjes Jacques, Driessen Christoph, Ludewig Burkhard, Hegazy Ahmed N, Jochum Wolfram, Speiser Daniel E, Zippelius Alfred, Läubli Heinz, Bomze David, Diem Stefan, Ali Omar Hasan, Fässler Mirjam, Ring Sandra, Niederer Rebekka, Ackermann Christoph J, Baumgaertner Petra, Pikor Natalia, Cruz Cristina Gil, van de Veen Willem, Akdis Mübeccel, Nikolaev Sergey, Flatz Lukas
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. J Immunother 2019; 42:89-93.
Apr 1, 2019Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment
Apr 1, 2019J Immunother 2019; 42:89-93
Diem Stefan, Risch Martin, Recher Mike, Risch Lorenz, Dummer Reinhard, Levesque Mitchell P, Mangana Joanna, Hillmann Dorothea, Niederer Rebekka, Berner Fiamma, Ali Omar Hasan, Bomze David, Fässler Mirjam, Flatz Lukas
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. J Immunother Cancer 2019; 7:50.
Feb 20, 2019Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
Feb 20, 2019J Immunother Cancer 2019; 7:50
Fässler Mirjam, Jörger Markus, Recher Mike, Risch Lorenz, Güsewell Sabine, Risch Martin, Speiser Daniel E, Ludewig Burkhard, Levesque Mitchell P, Dummer Reinhard, Siano Marco, Krolik Michal, Diem Stefan, Mangana Joanna, Hasan Ali Omar, Berner Fiamma, Bomze David, Ring Sandra, Niederer Rebekka, Gil Cruz Cristina, Pérez Shibayama Christian Ivan, Flatz Lukas
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer 2018; 107:8-14.
Dec 7, 2018Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors
Dec 7, 2018Eur J Cancer 2018; 107:8-14
Hasan Ali Omar, Lenz Tobias L, Driessen Christoph, Früh Martin, Jörger Markus, Cozzio Antonio, Diem Stefan, Fässler Mirjam, Bomze David, Berner Fiamma, Flatz Lukas
Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. Cancer Manag Res 2018; 10:5537-5544.
Nov 8, 2018Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment
Nov 8, 2018Cancer Manag Res 2018; 10:5537-5544
Diem Stefan, Früh Martin, Güsewell Sabine, Schmid Sabine, Ackermann Christoph Jakob, Roux Guillaume-Alexandre, Berner Fiamma, Niederer Rebekka, Siano Marco, Ali Omar Hasan, Fässler Mirjam, Flatz Lukas
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother 2018
Aug 31, 2018Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Aug 31, 2018Cancer Immunol Immunother 2018
Schmid Sabine, Jochum Wolfram, Klingbiel Dirk, Desbiolles Lotus, Leschka Sebastian, Flatz Lukas, Krapf Mirjam, Li Qiyu, Diem Stefan, Früh Martin
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. Cancer Immunol Immunother 2017; 67:39-45.
Sep 11, 2017Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease
Sep 11, 2017Cancer Immunol Immunother 2017; 67:39-45
Diem Stefan, Hasan Ali Omar, Ackermann Christoph J, Bomze David, Koelzer Viktor H, Jochum Wolfram, Speiser Daniel E, Mertz Kirsten D, Flatz Lukas
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017; 111:176-181.
Jul 24, 2017Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Jul 24, 2017Lung Cancer 2017; 111:176-181
Diem Stefan, Schmid Sabine, Krapf Mirjam, Flatz Lukas, Born Diana, Jochum Wolfram, Templeton Arnoud J, Früh Martin
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
Gobba S, Gaidano G, Pinotti G, Hitz F, Stathis A, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Iacoboni G, Cascione L, Diem S, Conconi A, Gulden-Sala W, Moccia A, Zucca E. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions. Hematol Oncol 2017
Jun 16, 2017Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions
Jun 16, 2017Hematol Oncol 2017
Gobba Stefania, Gaidano Gianluca, Pinotti Graziella, Hitz Felicitas, Stathis Anastasios, Aprile von Hohenstaufen Kathrin, Margiotta-Casaluci Gloria, Iacoboni Gloria, Cascione Luciano, Diem Stefan, Conconi Annarita, Gulden-Sala Wiebke, Moccia Alden A, Zucca Emanuele